Adaptive Biotechnologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADPT and other ETFs, options, and stocks.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. 

CEO
Chad Robins
CEOChad Robins
Employees
624
Employees624
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2009
Founded2009
Employees
624
Employees624

ADPT Key Statistics

Market cap
2.73B
Market cap2.73B
Price-Earnings ratio
-53.02
Price-Earnings ratio-53.02
Dividend yield
Dividend yield
Average volume
2.26M
Average volume2.26M
High today
$18.23
High today$18.23
Low today
$17.01
Low today$17.01
Open price
$17.15
Open price$17.15
Volume
2.99M
Volume2.99M
52 Week high
$20.76
52 Week high$20.76
52 Week low
$9.90
52 Week low$9.90

Stock Snapshot

With a market cap of 2.73B, Adaptive Biotechnologies(ADPT) trades at $17.07. The stock has a price-to-earnings ratio of -53.02.

During the trading session on 2026-06-10, Adaptive Biotechnologies(ADPT) shares reached a daily high of $18.23 and a low of $17.01. At a current price of $17.07, the stock is +0.4% higher than the low and still -6.4% under the high.

Trading activity shows a volume of 2.99M, compared to an average daily volume of 2.26M.

Over the past 52 weeks, Adaptive Biotechnologies(ADPT) stock has traded between a high of $20.76 and a low of $9.90.

Over the past 52 weeks, Adaptive Biotechnologies(ADPT) stock has traded between a high of $20.76 and a low of $9.90.

ADPT News

Simply Wall St 18h
Is Adaptive Biotechnologies Turning clonoSEQ’s MRD Momentum Into a Durable Competitive Moat?

In late May 2026, Adaptive Biotechnologies announced that its NGS-based clonoSEQ MRD test was featured in 33 presentations, including a plenary and 14 oral sess...

Is Adaptive Biotechnologies Turning clonoSEQ’s MRD Momentum Into a Durable Competitive Moat?
TipRanks 1d
Adaptive Biotechnologies Shareholders Back Board, Pay and Auditor

Adaptive Biotechnologies ( (ADPT) ) just unveiled an update. At its annual meeting of shareholders held on June 5, 2026, Adaptive Biotechnologies shareholders...

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.